US stock · Healthcare sector · Medical Devices
G
Glaukos Corporation
GKOS
NYSE62.61
USD
+0.49
(+0.79%)
After Hours Market
-21.37P/E
-34Forward P/E
-0.87P/E to S&P500
3.018BMarket CAP
- -Div Yield
Upcoming Earnings
1 Aug-7 Aug
Shares Short
5/15/23
5.48M
Short % of Float
16.42%
Short % of Shares Outs.
11.37%
% Held by Insiders
3.86%
% Held by Institutions
99.43%
Beta
1.24
PEG Ratio
-3.44
52w. high/low
63.61/40.45
Avg. Daily Volume
0.39M
Return %
Stock
S&P 500
1 year
45.82
3.92
3 years
42.71
37.71
5 years
64.69
56.01
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
33.92
18.53
39.82
14.25
52.49
23.07
70.91
25.25
84.65
50.60
76.20
23.31
99.00
39.35
64.49
33.33
63.61
42.48
Currency: USD
- -
- -
- -
- -
- -
- -
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
- -
- -
- -
- -
- -
- -
0.84
1.91
4.10
3.47
4.63
5.13
6.34
5.06
6.29
5.96
8.10
Earnings per share
- -
- -
- -
- -
- -
- -
(0.51)
(0.51)
(2.13)
0.14
(0.00)
(0.37)
0.41
(2.70)
(1.06)
(2.09)
(2.92)
FCF per share
- -
- -
- -
- -
- -
- -
(0.57)
(0.33)
(0.18)
0.18
0.56
0.24
(0.14)
(0.67)
(0.49)
(1.34)
(2.83)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
- -
0.03
0.04
0.05
0.19
0.18
0.29
0.13
0.16
1.02
0.64
0.66
Book Value per sh.
- -
- -
- -
- -
- -
- -
0.60
0.25
5.45
3.56
4.02
4.92
18.02
15.00
12.56
11.17
15.06
Comm.Shares outs.
- -
- -
- -
- -
- -
- -
25
24
17
33
34
35
37
44
47
47
36
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
(12.6)
193.5
(14,440.0)
(122.1)
164.3
(17.9)
(65.0)
(23.9)
(21.4)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
(0.6)
8.7
(612.1)
(4.9)
6.8
(0.5)
(2.2)
(1.1)
(0.9)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
- -
21
46
72
114
159
181
237
225
294
283
289
Operating margin
- -
- -
- -
- -
- -
- -
(67.8)%
(28.9)%
(14.4)%
3.7%
(1.4)%
(7.2)%
(21.2)%
(54.9)%
(11.2)%
(29.1)%
(43.8)%
Depreciation (m)
- -
- -
- -
- -
- -
- -
1
4
4
5
5
6
10
35
34
32
(2)
Net profit (m)
- -
- -
- -
- -
- -
- -
(13)
(12)
(37)
5
(0)
(13)
15
(120)
(50)
(99)
(139)
Income tax rate
- -
- -
- -
- -
- -
- -
(0.0)%
(0.1)%
(0.1)%
0.9%
9,300.0%
(4.7)%
130.8%
9.0%
(0.7)%
(0.8)%
(0.4)%
Net profit margin
- -
- -
- -
- -
- -
- -
(60.3)%
(26.6)%
(51.9)%
4.0%
(0.1)%
(7.1)%
6.5%
(53.5)%
(16.9)%
(35.1)%
(48.1)%
Working capital (m)
- -
- -
- -
- -
- -
- -
6
(10)
84
103
123
146
205
420
423
372
64
Long-term debt (m)
- -
- -
- -
- -
- -
- -
18
9
1
- -
- -
- -
73
271
382
382
- -
Equity (m)
- -
- -
- -
- -
- -
- -
15
6
95
117
138
174
673
667
587
530
509
ROIC
- -
- -
- -
- -
- -
- -
(37.2)%
(72.8)%
(37.6)%
4.4%
(3.0)%
(7.3)%
1.9%
(11.2)%
(3.7)%
(9.2)%
(13.2)%
Return on capital
- -
- -
- -
- -
- -
- -
(31.9)%
(31.5)%
(31.0)%
3.8%
0.0%
(6.0)%
(5.8)%
(11.8)%
(3.4)%
(8.5)%
(13.0)%
Return on equity
- -
- -
- -
- -
- -
- -
(84.8)%
(199.4)%
(39.1)%
3.9%
(0.1)%
(7.4)%
2.3%
(18.0)%
(8.4)%
(18.7)%
(27.4)%
Plowback ratio
- -
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
4 May · 2023 | Q1
All numbers in millions
Total liabilities
$ 464
Total assets
$ 973
Long-term debt
$ - -
Cash and equiv.
$ 76
Goodwill
$ - -
Retained earnings
$ - -
Common stock
- -
Enterprise Value
$ 2,942
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
404
414
353
Receivables
36
33
36
Inventory
16
23
38
Other
13
20
40
Current assets
469
486
444
Acc. Payable
4
7
14
Debt due
- -
- -
- -
Other
45
56
58
Current liabilities
50
63
72
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(3.79)%
13.14%
37.79%
Cash flow
174.51%
119.90%
26.71%
Earnings
100.02%
(264.53)%
1,434.21%
Dividends
- -
- -
- -
Book value
(9.73)%
66.16%
193.10%
Insider Trading
Type
Shares
Date
Burns Thomas William
Exempt
1
05/19/23
Burns Thomas William
Sale
1
05/19/23
Burns Thomas William
Exempt
7
05/23/23
Burns Thomas William
Sale
7
05/23/23
Burns Thomas William
Exempt
1
05/19/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
68
78
75
73
294
2022
68
73
71
71
283
2023
74
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
(0.35)
(0.37)
0.13
(0.47)
(1.06)
2022
0.11
(0.96)
(0.58)
(0.66)
(2.09)
2023
(Infinity)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Thomas William Burns
Full-time employees:
783
City:
San Clemente
Address:
229 Avenida Fabricante
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.